Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

INTRODUCTION: While adalimumab is licensed for ankylosing spondylitis (AS), open uncontrolled studies suggest therapeutic efficacy of TNF-inhibitors in juvenile onset AS (JoAS). METHODS: A total of 32 patients aged 12 to 17 years with severe, active and refractory JoAS were enrolled in a multicenter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Horneff, Gerd, Fitter, Sigrid, Foeldvari, Ivan, Minden, Kirsten, Kuemmerle-Deschner, Jasmin, Tzaribacev, Nicolay, Thon, Angelika, Borte, Michael, Ganser, Gerd, Trauzeddel, Rolf, Huppertz, Hans-Iko
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3580542/
https://ncbi.nlm.nih.gov/pubmed/23095307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4072
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados